Trial Profile
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil/rosuvastatin (Primary) ; Candesartan cilexetil; Rosuvastatin
- Indications Essential hypertension; Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Alvogen Korea
- 12 Jul 2019 Results published in the Clinical Therapeutics
- 23 Dec 2016 Status changed from recruiting to completed.
- 18 May 2016 New trial record